PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
PAVmed reported Q1 2026 revenue of $22,000 and a GAAP net loss of $7.0 million, driven by $8.1 million in operating expenses. Subsidiary Lucid Diagnostics (LUCD) generated $1.3 million in revenue from 3,177 EsoGuard tests and strengthened its balance sheet with $17 million in net proceeds from a recent offering, ending the quarter with $45 million in proforma cash.
Key figures
- Revenue
- 22000
- Lucid revenue
- 1300000
- Lucid proceeds net
- 17000000
- Operating expenses
- 8057000
- Lucid proforma cash
- 45000000
- Cash and equivalents
- 6500000
- Lucid tests processed
- 3177
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.